Conversely, population studies have found no association between increased risk of diabetic retinopathy and GLP-1 RA use [104, 105], with a low odds ratio observed for exenatide (OR 0.16), liraglutide (OR 0.18), albiglutide (OR 0.09), and dulaglutide (OR 0.11) [106]
Additionally, GLP-1 medications can affect gut motility throughout the entire digestive system, not just the stomach
Why GLP-1s entered the Alzheimers conversation There is a real reason GLP-1 medications are being studied in relation to the brain
The timing and intensity of gastrointestinal side effects differ by product and person, so patients should choose a time that best manages their symptoms whilst maintaining consistent adherence
In our practice, constipation is one of the most consistently reported problems on GLP-1 therapy, particularly in the first weeks of a new dose